Status:

NOT_YET_RECRUITING

T-cell Therapy in Patients With PML

Lead Sponsor:

Hannover Medical School

Conditions:

Progressive Multifocal Leucoencephalopathy (PML)

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

There is no approved standard treatment für progressive multifocal leukoencephalopathy (PML). The sponsor of the study is developing a new treatment. For this reason, the investigational medicinal pro...

Detailed Description

Progressive multifocal leukoencephalopathy (PML) is a severe infection of the central nervous system (CNS) caused by reactivation of human polyoma virus 2 (HPyV-2). HPyV-2 usually produces asymptomati...

Eligibility Criteria

Inclusion

  • Adults\* aged ≥ 18 years with PML (diagnosed ≤ 60 days before screening) associated with one or more of the following risk factors: lymphoproliferative diseases, immunosuppressive therapy, or lymphopenia
  • Signed written informed consent from subject and/or legal representative
  • HPyV-2 detection in CSF by PCR analysis or in brain biopsy

Exclusion

  • PML caused by HIV
  • PML caused by natalizumab
  • PML occurring within five 5 years after hematopoietic stem-cell transplantation or CAR T cell therapy, or resulting from chronic lymphocytic leukemia (CLL)
  • Patients who are unable to follow the study protocol, either on their own or with the support of a reliable representative, will be excluded
  • Pregnancy or breastfeeding
  • Currently receiving chemotherapy
  • Present (within 2 weeks before screening visit) and continuous treatment with immune checkpoint inhibition therapy
  • Severe infections other than PML (e.g. sepsis, pneumonia)
  • Hypersensitivity to any of the components of the medications used
  • Inability to undergo MRI examination (e.g. implanted incompatible medical devices, claustrophobia)
  • Participation in another clinical trial (other investigational drugs or devices at the time of enrolment or within 30 days prior to enrolment)

Key Trial Info

Start Date :

November 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 1 2027

Estimated Enrollment :

23 Patients enrolled

Trial Details

Trial ID

NCT06990087

Start Date

November 1 2025

End Date

November 1 2027

Last Update

November 24 2025

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

T-cell Therapy in Patients With PML | DecenTrialz